


Cardiogenic Shock and IABP

Quick Reference Guide

GETINGE 



Stages of Cardiogenic Shock¹

Cardiogenic Shock Stages	<h2>At Risk</h2> <p>A patient with risk factors for cardiogenic shock who is not currently experiencing signs or symptoms. For example, large acute myocardial infarction, prior infarction, acute and/or acute on chronic heart failure.</p>	<h2>Beginning</h2> <p>A patient who has clinical evidence of relative hypotension or tachycardia without hypoperfusion.</p>	<h2>Classic</h2> <p>A patient presenting with hypoperfusion requiring intervention beyond volume resuscitation (inotrope, pressor, or mechanical support including ECMO). These patients typically present with relative hypotension.</p>	<h2>Deteriorating</h2> <p>A patient who fails to respond to initial interventions. Similar to Stage C and getting worse.</p>	<h2>Extremis</h2> <p>A patient being supported by multiple interventions who may be experiencing cardiac arrest with ongoing CPR and/or ECMO.</p>
Physical Signs	<ul style="list-style-type: none"> • Normal JVP • Lung sounds clear • Strong distal pulses • Normal mentation 	<ul style="list-style-type: none"> • Elevated JVP • Rales in lung fields • Strong distal pulses • Normal mentation 	<ul style="list-style-type: none"> • Ashen, mottled, dusky • Volume overload • Extensive rales • Killip class 3 or 4 • Non-invasive or invasive ventilation • Acute alternation in mental status • Urine Output < 30 mL/h 	<ul style="list-style-type: none"> • Any of stage C 	<ul style="list-style-type: none"> • Near pulselessness • Cardiac collapse • Mechanical ventilation • Defibrillator used

Stages of Cardiogenic Shock, continued

Biochemical Markers	<ul style="list-style-type: none"> • Normal renal function • Normal lactate 	<ul style="list-style-type: none"> • Normal lactate • Minimal renal function impairment • Elevated BNP 	<ul style="list-style-type: none"> • Lactate ≥ 2 • Creatinine doubling OR $> 50\%$ drop in GFR • Increased LFTs • Elevated BNP 	<ul style="list-style-type: none"> • Any of stage C AND deteriorating 	<ul style="list-style-type: none"> • Lactate ≥ 5 • pH ≤ 7.2
	Hemodynamics	<ul style="list-style-type: none"> • Normotensive (SBP > 100 OR normal for pt.) <p>If hemodynamics done:</p> <ul style="list-style-type: none"> • Cardiac index ≥ 2.5 • CVP < 10 • PA Sat $\geq 65\%$ 	<ul style="list-style-type: none"> • SBP < 90 OR MAP < 60 OR > 30 mmHg drop • Pulse ≥ 100 <p>If hemodynamics done:</p> <ul style="list-style-type: none"> • Cardiac index ≥ 2.2 • PA Sat $\geq 65\%$ 	<ul style="list-style-type: none"> • Drugs/device used to maintain BP above stage B values <p>If hemodynamics done:</p> <ul style="list-style-type: none"> • Cardiac Index < 2.2 • RAP/PCWP > 0.8 • PCWP > 15 • PAPI < 1.85 • CPO ≤ 0.6 	<ul style="list-style-type: none"> • Any of stage C AND requiring multiple pressors OR addition of mechanical circulatory support devices to maintain perfusion

Adapted from the SCAI Clinical Expert Consensus Statement on the Classification of Cardiogenic Shock. Endorsed by ACC, AHA, SCCM, and STS.

Develop a Treatment Plan



Identify

Any attempt to improve outcomes in CS should begin with its early identification. Models of care including a multi-disciplinary CS team, hold potential for the early identification and individualized treatment of CS.²



Initiate

Experts suggest use of advanced hemodynamic monitoring to diagnose and/or manage patients with CS.¹ To avoid the negative impact of inotropes, consideration should be given to early initiation of intra-aortic balloon pumping.^{3,4}



Evaluate

Quick feedback loops incorporating patient status and hemodynamics are required to assess the response to initial therapies.⁵




Escalate

If patients do not respond to treatments initiated, consider the next level of support and transfer to experienced shock centers if required.¹




Benefits of IABP Therapy⁶



- ↑ Coronary Perfusion Pressure
- ↑ Coronary Blood Flow
- ↑ Myocardial Oxygen Supply

Diastolic Augmentation

Difference between non-augmented and augmented diastolic pressure



- ↓ LV Wall Tension/Afterload
- ↓ LVEDP
- ↑ Cardiac Output
- ↓ Myocardial Oxygen Demand

Systolic Unloading

Difference between unassisted systole and assisted systole pressure


IABP Proper Timing

Inflation


- Occurs at the diastolic notch
- Appears as a sharp "V"
- Ideally diastolic augmentation rises above systole

Deflation

- Occurs just prior to systolic ejection
- Results in a reduction in assisted end diastolic pressure
- Results in a reduction in assisted systolic pressure



Timing Errors



Early Inflation


Inflation of IAB prior to aortic valve closure.

Waveform characteristics

- Inflation of IAB prior to dicrotic notch
- Diastolic augmentation encroaches onto systole (may be unable to distinguish)

Physiologic Effects

- Potential premature closure of aortic valve
- Potential increase in LVEDV/LVEDP/PCWP
- Increased left ventricular wall stress or afterload
- Aortic regurgitation
- Increased MVO₂ demand



Late Inflation

Inflation of IAB markedly after closure of aortic valve.


Waveform characteristics

- Inflation of IAB after dicrotic notch
- Absence of sharp "V"
- Sub-optimal diastolic augmentation

Physiologic Effects

- Sub-optimal coronary artery perfusion

Timing Errors



Early Deflation


Premature deflation of IABP during diastolic phase.

Waveform characteristics

- Deflation of IABP is seen as a sharp drop following diastolic augmentation
- Sub-optimal diastolic augmentation
- Assisted end diastolic pressure may be equal to or less than unassisted end diastolic pressure
- Assisted systolic pressure may rise

Physiologic Effects

- Sub-optimal coronary perfusion
- Potential for retrograde coronary and carotid blood flow
- Angina may occur as a result of retrograde coronary blood flow
- Sub-optimal afterload reduction
- Increased MVO_2 demand



Late Deflation

Deflation of IABP after aortic valve has opened.

Waveform characteristics

- Assisted end diastolic pressure may be equal to or higher than unassisted end diastolic pressure
- Rate of rise of assisted systole is prolonged
- Diastolic augmentation may appear widened


Physiologic Effects

- Afterload reduction is essentially absent
- Increased MVO_2 consumption due to left ventricle ejecting against a greater resistance and a prolonged isovolumetric contraction phase
- IABP may impede left ventricular ejection and increase afterload

Blood pressure differences between the IABP monitor and the patient's bedside monitor


- The IABP displays assisted and unassisted systolic and diastolic pressures as well as the augmented diastolic pressure.
- Patient monitors do not have the capability of displaying both systolic and diastolic augmentation or differentiating assisted from unassisted systolic or diastolic pressures.
- Some bedside monitors analyze the arterial waveform over several seconds and display an average of the highest and lowest pressure points measured during the sampling period. They are not programmed to distinguish between a high pressure point generated by a patient's intrinsic systole or by balloon inflation during diastole.⁷
- It is both confusing and inaccurate to record "blood pressure" from the bedside digital display during balloon pumping.¹
- Serious errors can occur if one nurse records systole as the patient's actual systolic pressure and another nurse erroneously documents systole as the high pressure point actually occurring during diastolic balloon inflation (augmented diastolic pressure).⁷
- Check with the bedside monitor manufacturer for further information on how the arterial pressures are calculated and displayed when an IABP is in use.

Arterial waveform: Peripheral vs. Central⁸




Mean Arterial Pressure on IABP

Augmentation increases the mean arterial pressure by increasing the time and pressure under the curve. The IABP samples the pressure every 4 seconds on the waveform to determine the mean pressure. The standard formula does not take into account the diastolic augmentation.







Proper care of inner lumen

- Minimize length of pressure tubing.
- Use **only** low compliance pressure tubing.
- Elevate flush bag at least 3' (91.44 cm) above transducer.
- A 3cc/hour continuous flow through inner lumen is recommended.
- If inner lumen becomes damped.
 - Aspirate and discard 3cc of blood.
 - If **unable** to aspirate blood, consider inner lumen clotted, cap lumen, provide alternate pressure source.
 - If **able** to aspirate blood, fast flush to clear pressure tubing for **at least 15 seconds** (with IABP on Standby).
 - **Do not** sample blood from inner lumen.



IAB Sizing Guide

 <p>< 5'0" (< 152 cm)</p>	 <p>5'0" to 5'4" (152 cm - 162 cm)</p>	 <p>5'4" to 6'0" (162 cm - 183 cm)</p>	 <p>5'4" & taller (≥ 162 cm)</p> <p>6' 5'</p>
<p>30 cc</p>	<p>40 cc</p>	<p>50 cc</p>	
<p>Mega 7.5 Fr.</p>	<p>Sensation Plus 7.5 Fr. Mega 7.5 Fr.</p>	<p>Sensation Plus 8 Fr. Mega 8 Fr.</p>	
<p>25 cc</p> <p>Linear 7.5 Fr.</p>	<p>34 cc</p> <p>Sensation 7 Fr. Linear 7.5 Fr.</p>	<p>40 cc</p> <p>Sensation 7 Fr. Linear 7.5 Fr.</p>	

Note: This information is to be used as a guidance only. Clinical information and patient factors such as torso length should be considered when selecting the appropriate balloon size. Sensation and Sensation Plus are fiber-optic IAB catheters.

Alarms

Augmentation below limit set



Diastolic Augmentation is lower than Systolic pressure



Probable Cause

Hemodynamic status has changed: \uparrow HR, \downarrow SV, \downarrow MAP.

Corrective Action

Attempt to optimize patient's hemodynamic status.

Alarm limit set too high.

Press AUG. ALARM key, decrease limit.


Alarms

Kink in IAB Catheter



Balloon Pressure Waveform: appears rounded

IAB Catheter Restriction






Probable Cause	Corrective Action
Restriction in IAB catheter or tubing.	Relieve restriction. if possible, press START.
Membrane has not completely unfolded. IAB remains in sheath.	Manually inflate and deflate IAB. Check markings on IAB and if IAB has not exited sheath, refer to IFU to reposition sheath relative to IAB catheter.

Alarms

Gas Loss in IAB Circuit



Balloon Pressure Waveform: slow rise to baseline



Probable Cause

A helium loss has been detected in IAB circuit.

Corrective Action

If blood observed - STOP pumping. Prepare for removal of IAB.

If blood is not observed, verify connections are tight.

If appropriate, perform an Autofill, then press START to resume pumping.

References

1. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. *Catheter Cardiovasc Interv.* 2019;94:29-37
2. Jones TL, Nakamura K, McCabe JM. Cardiogenic shock: evolving definitions and future directions in management. *Open Heart* 2019;6:e000960.
3. Gul et al. Usefulness of Intra-aortic Balloon Pump in Patients with Cardiogenic Shock. *Am J Cardiol.* 2019 Mar 1;123(5):750-756. doi: 10.1016/j.amjcard.2018.11.041. Epub 2018 Dec 4
4. den Uil et al. Primary Intra-aortic Balloon Support versus Inotropes for Decompensated Heart Failure and Low Output: A Randomized Trial. *EuroIntervention* 2019;15:586-593.
5. Atkinson TM, Ohman EM, O'Neill WW, Rab T, Cigarroa JE. Interventional Scientific Council of the American College of Cardiology. A Practical Approach to Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention: An Interventional Perspective. *JACC Cardiovasc Interv.* 2016 May 9;9(9):871-83.
6. Parissis, H., Graham, V., Lampridis, S. et al. IABP: history-evolution-pathophysiology-indications: what we need to know. *J Cardiothorac Surg* 11, 122 (2016).
7. Quaal, SJ. Interpreting the Arterial Pressure Waveform in Intra-aortic Balloon Pump Patients. *Prog Cardiovascular Nurs.* 2001;16(3).
8. Schroeder, RA. Cardiovascular Monitoring. Chapter 40. *Miller's Anesthesia.* 7th Edition. Saunders; 2007



PN: 0002-08-9881 Rev A · ***GETINGE** ✱, Getinge, and Maquet are trademarks or registered trademarks of Getinge AB, its subsidiaries, or affiliates in the United States or other countries · Copyright 2020 Datascope Corp. · All rights reserved · CAUTION: Federal (U.S.A.) law restricts this device to sale, distribution and use by or on the order of a physician. ΔRefer to Instructions for Use for current indications, warnings, contraindications and precautions · 09/2020

Manufacturer · Datascope Corp., 1300 MacArthur Blvd., Mahwah, NJ 07430 · USA · +1 201 995-8700 or 1 800 777-4222

www.getinge.com